supp. cum glycerol et gelatin pbv medica baby supp.
laboratoria qualiphar sa-nv - glycerol 65 g/100 g - suppository - glycerol 650 mg/g - glycerol
supp. cum glycerol et gelatin pbv medica kids supp.
laboratoria qualiphar sa-nv - glycerol 65 g/100 g - suppository - glycerol 650 mg/g - glycerol
supp. cum glycerol et gelatin pbv medica adult supp.
laboratoria qualiphar sa-nv - glycerol 65 g/100 g - suppository - glycerol 650 mg/g - glycerol
glycerol 4g suppositories
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - glycerol - suppository - glycerol 2800 mg - drugs for constipation
glycerol 1g suppositories
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - glycerol - suppository - glycerol 700 mg - drugs for constipation
r-zero ethyl alcohol antiseptic hand sanitizing fragrance- ethyl alcohol gel
r-zero systems, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic • hand sanitizer to decrease bacteria on the skin • recommended for repeated use • for use when soap and water are not available
glycerol
psm healthcare ltd trading as api consumer brands - glycerol 3.6 g; ; - suppository - 3.6 g - active: glycerol 3.6 g excipient: gelatin purified water
glycerol suppositories
noumed pharmaceuticals limited - glycerol 70%{relative}; - suppository - 3.6 g - active: glycerol 70%{relative} excipient: gelatin methyl hydroxybenzoate purified water
pacerone- amiodarone hydrochloride tablet
upsher-smith laboratories, llc - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 100 mg - pacerone is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. - cardiogenic shock. - sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker. - known hypersensitivity to the drug or to any of its components, including iodine. risk summary available data from post-marketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventricular arrhythmias, during
pacerone- amiodarone hydrochloride tablet
physicians total care, inc. - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - because of its life-threatening side effects and the substantial management difficulties associated with amiodarone use (see "warnings" below), pacerone® (amiodarone hcl) tablets are indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. - recurrent ventricular fibrillation. - recurrent hemodynamically unstable ventricular tachycardia. as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hcl tablets favorably affects survival. pacerone® (amiodarone hcl) tablets should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and amb